Dynamics of the Upper and Lower Airway Respiratory Microbiomes Associated With Severe Infant Asthma (Microbiosthme)

University Hospital, Rouen

Status

Enrolling

Conditions

Asthma

Asthma in Children

Treatments

Other: Blood sample

Other: Expectoration

Other: Nasopharyngeal swab

Study type

Interventional

Funder types

Other

Identifiers

NCT06044051

2023/0091/OB

Details and patient eligibility

About

Nature of potential dysbiosis, interrelation of the different microbiomes of the respiratory tract, and potential role of the immune system in the pathogenesis of severe asthma in infants, and its evolution under treatment.

Exploring and understanding these data is to improve patient care and discover new therapeutic targets.

The aim is to open up prospects for therapeutic studies, such as the use of azithromycin as an immunomodulator in infant asthma, the results of which are discordant.

Enrollment

100 estimated patients

Sex

All

Ages

Under 24 months old

Volunteers

No Healthy Volunteers

Inclusion criteria

Infants less than 24 months old
Follow-up by a pneumo-pediatrician for severe asthma in infants
Requiring etiological investigations and assessment of severity in day hospitalization, including bronchial fibroscopy (HAS 2009)
Parent informed of the research and having signed consent

Exclusion criteria

Prematurity <32 WA
Congenital heart disease with significant left to right shunt
Chronic respiratory disease other than infant asthma (cystic fibrosis, bronchiolitis obliterans)
Antibiotic therapy in progress or administered the seven days preceding the date of inclusion (day hospitalization)
Refusal of bronchial fibroscopy